Cargando…

Introduction of multi-dose PCV 13 vaccine in Benin: from the decision to vaccinators experience

BACKGROUND: In 2011, Benin introduced the 13-valent pneumococcal conjugated vaccine (PCV13), in a single-dose vial, into its Expanded Programme for Immunisation (EPI) with support from Gavi. In April 2018, with the support of the Agence de Médecine Préventive Afrique (AMP) and other technical and fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdoulaye Alfa, Daleb, Houngnihin, Roch A., Ilboudo, G. Patrick, Dick, Naomi, Kaucley, Landry, Essoh, Téné-Alima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7414647/ https://www.ncbi.nlm.nih.gov/pubmed/32770996 http://dx.doi.org/10.1186/s12889-020-09326-9

Ejemplares similares

The economic impact of the switch from single- to multi-dose PCV13 vial in Benin
por: Ilboudo, Patrick G., et al.
Publicado: (2022)

Cartographie, profil et formation des acteurs de la vaccination, Bénin, 2020
por: APLOGAN, Aristide, et al.
Publicado: (2023)

Caregivers’ Willingness to Vaccinate Their Children against Childhood Diseases and Human Papillomavirus: A Cross-Sectional Study on Vaccine Hesitancy in Malawi
por: Adeyanju, Gbadebo Collins, et al.
Publicado: (2021)

Exploring the factors contributing to low vaccination uptake for nationally recommended routine childhood and adolescent vaccines in Kenya
por: Essoh, Tene-Alima, et al.
Publicado: (2023)

Cost-effectiveness analysis of routine immunization and supplementary immunization activity for measles in a health district of Benin
por: Kaucley, Landry, et al.
Publicado: (2015)

Examining enablers of vaccine hesitancy toward routine childhood and adolescent vaccination in Malawi
por: Adeyanju, Gbadebo Collins, et al.
Publicado: (2022)

Social Engagement in the Fight Against COVID-19 in the Urban and Peri-Urban Areas of Cotonou (Benin, Sub-saharan Africa): Acceptability of the Vaccination and Tracking Program
por: Maccaro, Alessia, et al.
Publicado: (2022)

2703. Pneumococcal Carriage of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Non-PCV13 Serotypes among Greek Children Vaccinated with PCV13 in a 3 + 1 Schedule During the First 6 years after the Fourth Dose of PCV13
por: Syrogiannopoulos, George A, et al.
Publicado: (2019)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)

Population genomics of pneumococcal carriage in South Africa following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) immunization
por: Javaid, Nida, et al.
Publicado: (2022)

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
por: Ansaldi, Filippo, et al.
Publicado: (2020)

1479. Incidence of Acute Otitis Media in Children in the United States before and after the introduction of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

Predictors to parental knowledge about childhood immunisation/EPI vaccines in two health districts in Cameroon prior to the introduction of 13-valent Pneumococcal Conjugate Vaccines (PCV-13)
por: Libwea, John Njuma, et al.
Publicado: (2014)

Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
por: Suwantika, Auliya A., et al.
Publicado: (2020)

1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018
por: Hu, Tianyan, et al.
Publicado: (2020)

Pneumococcal Meningitis in Adults after Introduction of PCV7 and PCV13, Israel, July 2009–June 2015
por: Regev-Yochay, Gili, et al.
Publicado: (2018)

Assessment of COVID-19 Vaccine Acceptance and Its Associated Factors during the Crisis: A Community-Based Cross-Sectional Study in Benin
por: Padonou, Sètondji Géraud Roméo, et al.
Publicado: (2023)

Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines
por: Hadjipanayis, Adamos, et al.
Publicado: (2016)

Response to PCV13 vaccination in patients with multiple myeloma versus healthy controls
por: Mustafa, S. Shahzad, et al.
Publicado: (2018)

Potentiating pneumococcal glycoconjugate vaccine PCV13 with saponin adjuvant VSA-1
por: Kim, Hyunjung, et al.
Publicado: (2022)

Understanding Hand Hygiene Behavior in a Public Hospital in Benin Using the Theoretical Domain Frameworks: The First Step for Designing Appropriate Interventions
por: Yehouenou, Carine Laurence, et al.
Publicado: (2022)

A bivalent porcine circovirus type 2 (PCV2), PCV2a-PCV2b, vaccine offers biologically superior protection compared to monovalent PCV2 vaccines
por: Bandrick, Meggan, et al.
Publicado: (2022)

Population structure, epidemiology and antibiotic resistance patterns of Streptococcus pneumoniae serotype 5: prior to PCV-13 vaccine introduction in Eastern Gambia
por: Ashu, Eta E., et al.
Publicado: (2016)

A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
por: Dirmesropian, S, et al.
Publicado: (2015)

1441. Doses of 13-Valent Conjugated Pneumococcal Vaccine (PCV13) for Patients With Multiple Myeloma (MM)
por: Sun, Hsin-Yun, et al.
Publicado: (2018)

1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
por: Buchwald, Ulrike, et al.
Publicado: (2018)

Understanding vaccine hesitancy with PCV13 in children: Results of a survey in Shanghai, China
por: Ni, Yi-hong, et al.
Publicado: (2023)

Population genomics of pneumococcal carriage in Massachusetts children following introduction of PCV-13
por: Mitchell, Patrick K., et al.
Publicado: (2019)

Response to article by Johnna Perdrizet et al.,“Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants”
por: Gómez, Jorge A., et al.
Publicado: (2021)

How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018
por: Wouters, Ine, et al.
Publicado: (2020)

1434. Cost-Effectiveness of Sequencial Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23 Valent Polysaccharide Vaccine (PPV23) in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Decision-making for PCV in adults
por: McLaughlin, John M., et al.
Publicado: (2018)

Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic
por: Tomczyk, Sara, et al.
Publicado: (2018)

Estimating the Clinical and Economic Impact of Maintaining use of 13-valent Pneumococcal Conjugate Vaccine (PCV13) in Mexico
por: Wasserman, Matt, et al.
Publicado: (2017)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

597 Increase in IPD incidence in Adults in 2013-2014 after 2 consecutive years of decline following introduction of 13-valent pneumococcal conjugate vaccine (PCV13)
por: Baxter, Roger, et al.
Publicado: (2014)

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
por: van der Linden, Mark, et al.
Publicado: (2016)

Durability of the deltamethrin-treated polypropylene long-lasting net LifeNet® in a pyrethroid resistance area in south western Benin: A phase III trial
por: Djènontin, Armel, et al.
Publicado: (2023)

Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
por: van der Linden, Mark, et al.
Publicado: (2015)

The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination
por: Slotved, Hans-Christian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8cok71gus124atkspon6q52vt5